Ophthalmic medical device company, Mynosys Cellular Devices, Inc., tells us it has received CE mark approval for the ZEPTO capsulotomy device. ZEPTO is a disposable automated capsulotomy device that provides surgeons with round, accurately sized, and well-centered capsulotomies without interrupting surgical routine and patient flow.
The Zepto capsulotomy device uses a highly focused multipulse low-energy discharge to produce a complete, round anterior capsulotomy simultaneously along 360 degrees within milliseconds. The ZEPTO handpiece, with its soft collapsible capsulotomy tip, is an alternative to manual capsulorhexis and allows capsulotomy alignment with the patient’s visual axis for optimized IOL placement and effective lens positioning. In use, the ZEPTO handpiece is connected to a small power console located away from the sterile field.
ZEPTO is targeted at ophthalmic surgeons who perform cataract surgery and it looks like the company has really done its homework on the market opportunity this represents: An in-depth market development analysis was conducted by an independent third party to evaluate ZEPTO’s projected rate of adoption, barriers, market penetration, and sizing. Detailed disease and patient segmentation, treatment landscape, and health care and government data were combined with validated statistical engines and behavioral change theory. The analysis revealed ZEPTO to be a compelling product with few barriers to adoption.
“The most compelling patient segment with comorbidities represents 25% of the cataract surgical population and is an ideal target segment to support rapid ZEPTO penetration to access the early majority. ZEPTO’s ease of use and superior performance will accelerate broad adoption to become the standard of care with minimal marketing and selling elements,” said John N. Hendrick, President and CEO of Mynosys.
Source: PR Web